Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.32 |
| ▸ | WNT3A | P56704 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.30 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7128688 | 1.00 | MMP2 (0.40) | MMP2MMP13HTR1DCTNNB1WNT3A | |
| SCHEMBL7123582 | 0.87 | MMP2 (0.39) | MMP2MMP13CTNNB1WNT3ABRD4 | |
| SCHEMBL7118832 | 0.87 | MMP2 (0.39) | MMP2MMP13CTNNB1WNT3ABRD4 | |
| SCHEMBL7118822 | 0.87 | MMP2 (0.39) | MMP2MMP13CTNNB1WNT3ABRD4 | |
| SCHEMBL7124787 | 0.84 | MMP2 (0.43) | MMP2MMP13HTR1DBRD4ATAD2 | |
| SCHEMBL7127879 | 0.84 | ADAMTS5 (0.40) | MMP2MMP13 | |
| SCHEMBL7127883 | 0.84 | ADAMTS5 (0.40) | MMP2MMP13 | |
| SCHEMBL7127890 | 0.84 | ADAMTS5 (0.40) | MMP2MMP13 | |
| SCHEMBL7124781 | 0.84 | MMP2 (0.43) | MMP2MMP13HTR1DBRD4ATAD2 | |
| SCHEMBL7157709 | 0.84 | MMP13 (0.39) | MMP2MMP13MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030134880-A1 | Novel cd23 inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-17 | — | — | US | claimed |
| US-20030134880-A1 | Novel cd23 inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134880-A1 | Novel cd23 inhibitors | CD2, CD22, CD40 | MMP2 1392/4885MMP13 335/4885HTR1D 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.